Pinnacle Spine

Executive Summary

Pinnacle Spine Group (PSG) is a privately-held medical device company based in Austin, Texas, dedicated to improving outcomes in lumbar spine fusion. Its patented InFill® Interbody Fusion System addresses the critical 'biologic void' by enabling controlled, in-situ delivery of bone graft material directly to vertebral endplates, optimizing fusion success. Since its founding in 2005, PSG has focused on commercialization and iterative innovation within the US spinal implant market. As a private entity, PSG operates with limited public financial disclosure, but its focused product portfolio and niche clinical solution position it for steady growth in the competitive spine surgery landscape. The company's value proposition centers on a differentiated technology that directly tackles a key failure mode in spinal fusion, potentially driving adoption among surgeons seeking improved patient outcomes.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation InFill system with enhanced delivery features70% success
• Q4 2026Publication of pivotal clinical study results demonstrating superior fusion rates with InFill60% success
• TBDStrategic partnership or distribution agreement with a major spine implant company40% success